

Name	<b>Daniele SANTINI; MD, PhD</b>
Birth Place and Date	
Fiscal Code-Nationality	
Languages	Italian, English (British Academy, VI level)
Permanent Address	00188 Rome, Italy, Via della Giustiniana 401
Present Occupation	Full Professor in Medical Oncology Campus Bio-Medico University of Rome
Phone-Fax	
Mobile	
E-mail	<b><u><a href="mailto:d.santini@unicampus.it">d.santini@unicampus.it</a></u></b>

### **A. Education and training**

<b>2001</b>	PhD in Immunopharmacology, University of Palermo
<b>1994</b>	Resident-Specialty in Medical Oncology (score 70/70), University "La Sapienza" of Rome
<b>1990</b>	M.D. graduated cum laude, University "La Sapienza" of Rome

### **B. Professional and Academic Appointments**

<b>2017 - Today</b>	Full Professor in Medical Oncology Campus Bio-Medico University of Rome
<b>2016 - Today</b>	Study Coordinator of Medicine and Surgery Degree Campus Bio-Medico University of Rome
<b>2015 - Today</b>	Associate Adjunct Professor in Biology, Temple University's College of Science and Technology, Philadelphia (USA)
<b>2013 - Today</b>	Member of Scientific Board of PhD Program: "Biomedical Sciences and Bio- Ethics, Campus Bio-Medico University of Rome
<b>2011 - Today</b>	Vice-director of Specialization School in Medical Oncology Campus Bio-Medico University of Rome
<b>2009 - Today</b>	Chief of Medical Oncology Day Hospital Campus Bio-Medico University-Hospital of Rome
<b>2007 – Today</b>	Co-chair of Oncology Research Unit Campus Bio-Medico University of Rome
<b>2010 - 2016</b>	Associate Professor in General Pathology Campus Bio-Medico University of Rome
<b>2007 - 2012</b>	Member of Scientific Board of PhD Program: "Osteoncological Physiopathology", Campus Bio-Medico University of Rome
<b>2001 - 2010</b>	Researcher in Medical Oncology Campus Bio-Medico University of Rome
<b>2006 - 2009</b>	In charge of high specialization professional activities,

Department of Medical Oncology, Campus Bio-Medico University of Rome

### **C. Teaching Activities, Campus Bio-Medico University of Rome**

Teacher of Immunology  
Medicine and Surgery Course

Teacher of General Pathology  
Alimentary Sciences and Nutrition Course

Teacher of General Pathology  
Radiological Technical Course

Didactic and tutorial activities in Oncology (Nursing course in General  
Medicine)  
Nursing Course

Teacher of Cellular and Humoral Immunity  
Hematology Specialization School

Teacher of Osteoncological Pathology and Methodology of Oncological  
Research  
Oncology Specialization School

Teacher of "Immunology  
Clinical Pathology Specialization,  
Microbiology and Virology Specialization School,  
Allergology Specialization School

Teacher of "General Pathology"  
Radiotherapy Specialization School

Teacher of Principles of General Pathology in Oncology  
General Surgery Specialization School

Teacher of Integrated therapies in Oncology  
Digestive System Surgery Specialization School

### **D. Awards, Research Competitive Calls**

- |                   |  |
|-------------------|--|
| <b>09/14/2018</b> | Special Award for Professional Career received by Italian Chamber of Deputies  |
| <b>2016</b>       | Co-winner research application "Bando Interno per progetti di ricerca utili a favorire la formazione di profili interdisciplinari in collaborazione tra l'Istituto FAST e le unità di ricerca dell'Ateneo sul tema dell'embodiment", Campus Bio-Medico University of Rome, Project Title: "SELF-ON-A-CHIP" |
| <b>2014-2015</b>  | Winner of the Bilateral project Italia-USA MAE<br>Project Title: "Understanding the interplay between cancer stem cells and immune system: an innovative cells-on-chip approach".  |
| <b>2013</b>       | Winner of Competition "Fondazione G. Berlucci for Cancer Research 2013"<br>Project Title: "Cell-on-chip models for the development of integrated therapies of immunotherapy with the aim to overcome the resistance to conventional treatments in non small cell lung cancer: the role of interaction      |

between cancer stem cells and macrophage polarization”.

- 2013** Co-winner research application PRIN 2012  
Project Title: “Cells-on-chip technologies for the study of endocannabinoid system in an in vivo model of cancer/immunity system interactions”.
- 2005** Scientific Director of the PRIN Research Unit PRIN 2005.  
Project Title: Modulation of Human Gamma/Delta T Lymphocytes and analysis of different biological parameters (Inflammatory cytokines, cytokines related to the immune response, pro-angiogenic factors, bone resorption markers) after zoledronic acid administration in patients with solid tumors.

#### **E. Cordinator, partecipation in the writing of national and international oncology guidelines**

- 2018** member of the “Genitourinary Faculty (GU)” for the European Society of Medical Oncology (ESMO)
- 2018** Co-author of Guidelines on “Orphan symptoms” for the European Society of Medical Oncology (ESMO)
- 2012** Co-author of Management of cancer pain: ESMO Clinical Practice Guidelines
- 2010-today** Coordinator of the National Guidelines on “Lung Bone metastases treatment” for the Italian Association of Toracic Oncology (AIOT)
- 2010-today** Co-author of the National Guidelines on “Prostate bone metastases treatment” for the Italian Society of Urology (SIU)
- 2008-today** Coordinator of the National Guidelines on “Bone metastases treatment” for the Italian Association of Medical Oncology (AIOM)

#### **F. Editorial Activity**

- 2014-today** **Accademic Editor** of PLOS ONE
- 2013-today** **Editor in chief** of Expert Opinion on Therapeutic Targets

**Member of the Editorial Board** of several International Scientific Journals: ESMO Open; Critical Review in Oncology and Haematology –CROH-; Cancer Biology and Therapy; Expert Opinion on Therapeutic Targets; Expert Opinion on Biological Therapy; Expert Opinion on Emerging Drugs; Pharmacogenomics; Journal of Experimental and Clinical Cancer Research; Women’s Health; Medic; Recent Patents on Anti -Cancer Drug Discovery; Therapy; Internet Journal of Oncology; Journal clinical medicine: oncology; World Journal Clinical Oncology; OncoTargets and Therapy; Journal of Chemotherapy; Clinical Cancer Drugs; BioMed Research International.OncoTargets.

#### **G. Scientific Societies’ membership, adsvisor, President and affiliations**

- 2014-today** National Advisor, South Italy Oncology Group (GOIM)
- 2014-today** National Advisor, North West Oncology Group (GONO)

**2015-2017** National President of Italian Society of Osteoncology (ISO)  
**2011-today** Regional Advisor, Italian Association of Medical Oncology (AIOM)

## H. Publications

500 publications on International journals with Impact Factor

**Scopus Citations:** 12647

**H-Index Scopus:** 52

## Relevant Publications

Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, **Santini D**. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. *JAMA Oncol.* 2018 Nov 21. doi: 10.1001/jamaoncol.2018.5080. [Epub ahead of print] PubMed PMID: 30476968; PubMed Central PMCID: PMC6439839. **IF: 22.416**

Dell'Aquila E, Cremolini C, Zeppola T, Lonardi S, Bergamo F, Masi G, Stellato M, Marmorino F, Schirripa M, Urbano F, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Fea E, Di Donato S, Chiara S, Tonini G, Tomcikova D, Boni L, Falcone A, **Santini D**. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. *Ann Oncol.* 2018 Apr 1;29(4):924-930. doi: 10.1093/annonc/mdy004. PubMed PMID: 29324972.  
**IF: 13.926**

**Santini D**, Brandi G, Aprile G, Russano M, Cereda S, Leone F, Lonardi S, Fornaro L, Scartozzi M, Silvestris N, Barni S, Pantano F, Vincenzi B, Palloni A, Frega G, Casagrande M, Ferrari L, Dadduzio V, Intini R, Filippi R, Vasile E, Vivaldi C, Faloppi L, Brunetti O, Reni M, Aglietta M, Tonini G. Bone metastases in biliary cancers: A multicenter retrospective survey. *J Bone Oncol.* 2018 Apr 7;12:33-37. doi: 10.1016/j.jbo.2017.11.006. eCollection 2018 Sep. PubMed PMID: 30042924; PubMed Central PMCID: PMC6054714. **IF: 2.866**

**Santini D**, Ratta R, Pantano F, De Lisi D, Maruzzo M, Galli L, Biasco E, Farnesi A, Buti S, Sternberg CN, Cerbone L, Di Lorenzo G, Spoto S, Sterpi M, De Giorgi U, Berardi R, Torniai M, Camerini A, Massari F, Procopio G, Tonini G. Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. *Oncotarget.* 2017 Aug 7;8(59):100708-100716. doi: 10.18632/oncotarget.20022. eCollection 2017 Nov 21. PubMed PMID: 29246014; PubMed Central PMCID: PMC5725056. **IF: 5.168**

Fioramonti M\*, **Santini D\***, Iuliani M, Ribelli G, Manca P, Papapietro N, Spiezia F, Vincenzi B, Denaro V, Russo A, Tonini G, Pantano F. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. *Oncotarget.* 2017 Mar 21;8(12):20113-20121. doi: 10.18632/oncotarget.15390. PubMed PMID: 28223547; PubMed Central PMCID: PMC5386748.  
**IF: 5.168** \*Co-first name

von Moos R, Costa L, Ripamonti CI, Niepel D, **Santini D**. Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain. *Eur J Cancer.* 2017 Jan;71:80-94. doi: 10.1016/j.ejca.2016.10.021. Epub 2016 Dec 14. Review. PubMed PMID: 27984770. **IF: 6.680**

**Santini D**, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G. Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. *Sci Rep.* 2016 Apr 15;6:22205. doi: 10.1038/srep22205. PubMed PMID: 27079142; PubMed Central PMCID: PMC4832177. **IF: 4.525**

**Santini D**, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. *Oncotarget.* 2016 May 31;7(22):33381-90. doi: 10.18632/oncotarget.8302. PubMed PMID: 27027342; PubMed Central PMCID: PMC5078103. **IF: 5.168**

**Santini D**, Tonini G. Treatment of Advanced Renal-Cell Carcinoma. *N Engl J Med.* 2016 Mar 3;374(9):888-9. doi: 10.1056/NEJMc1515613#SA2. PubMed PMID: 26962913. **IF 79.258**

**Santini D**, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G. Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. *Sci Rep.* 2015 Dec 22;5:18670. doi: 10.1038/srep18670. Erratum in: *Sci Rep.* 2016;6:22205. multiple author names corrected. PubMed PMID: 26690845; PubMed Central PMCID: PMC4687045. **IF: 5.168**

Santoni M, Scarpelli M, Lopez-Beltran A, Cheng L, Briganti A, Montorsi F, Montironi R, **Santini D**. Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. *Eur Urol* 2015;68:542-3. *Eur Urol.* 2016 Sep;70(3):e69-70. doi: 10.1016/j.eururo.2015.09.022. Epub 2015 Oct 1. PubMed PMID: 26431914. **IF: 17.298**

Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body JJ, Markopoulos C, **Santini D**, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. *Ann Oncol.* 2016 Mar;27(3):379-90. doi: 10.1093/annonc/mdv617. Epub 2015 Dec 17. Review. PubMed PMID: 26681681. **IF: 13.926**

Iuliani M, Pantano F, Buttigliero C, Fioramonti M, Bertaglia V, Vincenzi B, Zoccoli A, Ribelli G, Tucci M, Vignani F, Berruti A, Scagliotti GV, Tonini G, **Santini D**. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. *Oncotarget.* 2015 May 20;6(14):12520-8. PubMed PMID: 25904051; PubMed Central PMCID: PMC4494955. **IF: 5.168**

Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida FM, Fontana A, Berruti A, Berardi R, Massari F, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, De Lisi D, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Luzi Fedeli S, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Montironi R, Bracarda S, Tonini G, Cascinu S, **Santini D**. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? *J Exp Clin Cancer Res.* 2015 Feb 5;34:10. doi: 10.1186/s13046-015-0122-0. PubMed PMID: 25651794; PubMed Central PMCID: PMC4328067. **IF: 6.127**

Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, Thompson SK, Zollo M, Spano D, Dhawan P, Sliva D, Subbarayan PR, Sarkar M, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Ye L, Helferich WG, Yang X, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Nowsheen

S, Pantano F, **Santini D**. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. *Semin Cancer Biol.* 2015 Dec;35 Suppl:S244-S275. doi: 10.1016/j.semcancer.2015.03.008. Epub 2015 Apr 10. Review. PubMed PMID: 25865774.  
**IF: 9.658**

**Santini D**, Pantano F, Riccardi F, Di Costanzo GG, Addeo R, Guida FM, Ceruso MS, Barni S, Bertocchi P, Marinelli S, Marchetti P, Russo A, Scartozzi M, Faloppi L, Santoni M, Cascinu S, Maiello E, Silvestris F, Tucci M, Ibrahim T, Masi G, Gnoni A, Comandone A, Fazio N, Conti A, Imarisio I, Pisconti S, Giommoni E, Cinieri S, Catalano V, Palmieri VO, Infante G, Aieta M, Trogu A, Gadaleta CD, Brunetti AE, Lorusso V, Silvestris N. Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. *PLoS One.* 2014 Aug 29;9(8):e105268. doi: 10.1371/journal.pone.0105268. eCollection 2014. PubMed PMID: 25170882; PubMed Central PMCID: PMC4149423. **IF: 2.776**

Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, **Santini D**, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Vecchia A, Conteduca V, Maines F, Galligioni E. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. *Eur Urol.* 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25. PubMed PMID: 25457020.  
**IF: 17.298**

Silvestris N, Pantano F, Ibrahim T, Gamucci T, De Vita F, Di Palma T, Pedrazzoli P, Barni S, Bernardo A, Febbraro A, Satolli MA, Bertocchi P, Catalano V, Giommoni E, Comandone A, Maiello E, Riccardi F, Ferrara R, Trogu A, Berardi R, Leo S, Bertolini A, Angelini F, Cinieri S, Russo A, Pisconti S, Brunetti AE, Azzariti A, **Santini D**. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. *PLoS One.* 2013 Oct 28;8(10):e74402. doi: 10.1371/journal.pone.0074402. eCollection 2013. PubMed PMID: 24204569; PubMed Central PMCID: PMC3810275. **IF: 2.776**

Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, **Santini D**, Rondena R, Bogani P, Ripamonti CI. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. *Lancet Oncol.* 2013 Jun;14(7):663-70. doi: 10.1016/S1470-2045(13)70174-8. Epub 2013 May 16. PubMed PMID: 23684411. **IF: 35.386**

**Santini D**, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. *Lancet Oncol.* 2012 Oct;13(10):1020-4. doi: 10.1016/S1470-2045(12)70373-X. Epub 2012 Sep 18. PubMed PMID: 22995650. **IF: 35.386**

**Santini D**, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto ME, Mazzara C, Latiano TP, Bertolini F, Petrelli F, Ottone A, Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Maiello E, Tonini G. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. *Ann Oncol.* 2012 Aug;23(8):2072-7. doi: 10.1093/annonc/mdr572. Epub 2012 Jan 4. PubMed PMID: 22219016. **IF: 13.926**

**Santini D**, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G. Receptor activator of NF- $\kappa$ B (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. *PLoS One.* 2011 Apr 29;6(4):e19234. doi: 10.1371/journal.pone.0019234. PubMed PMID: 21559440; PubMed Central PMCID: PMC3084800.  
**IF: 2.776**

**Santini D**, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. *J Cell Physiol*. 2011 Mar;226(3):780-4. doi: 10.1002/jcp.22402. PubMed PMID: 20857484. **IF: 4.522**

**Santini D**, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. *Clin Cancer Res*. 2007 Aug 1;13(15 Pt 1):4482-6. PubMed PMID: 17671133. **IF: 10.199**

**Santini D**, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. *Clin Cancer Res*. 2003 Aug 1;9(8):2893-7. PubMed PMID: 12912933. **IF: 10.199**

**Santini D**, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G. Pamidronate induces modifications of circulating angiogenic factors in cancer patients. *Clin Cancer Res*. 2002 May;8(5):1080-4. PubMed PMID: 12006522. **IF: 10.199**